Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1990 Aug;49(8):582–586. doi: 10.1136/ard.49.8.582

Polymorphism of major histocompatibility complex extended haplotypes bearing HLA-DR3 in patients with rheumatoid arthritis with gold induced thrombocytopenia or proteinuria.

D P Singal 1, B Reid 1, D Green 1, M D'Souza 1, W G Bensen 1, W W Buchanan 1
PMCID: PMC1004168  PMID: 2396862

Abstract

The distribution of DR3 and of extended haplotypes bearing DR3 was studied in three groups of subjects: 35 patients with rheumatoid arthritis (RA) with gold induced thrombocytopenia or proteinuria, 185 patients with RA without these side effects, and 300 normal healthy controls. The extended haplotypes bearing DR3 were analysed with cDNA probes for DR alpha, DR beta, DQ alpha, and DQ beta genes. The data showed that the prevalence of DR3 was significantly higher in patients who developed gold induced thrombocytopenia or proteinuria than in normal controls or patients with RA without these side effects. Distribution of three extended haplotypes bearing DR3 (B8, DR3; B18,DR3; non-B8,non-B18,DR3) in patients with RA with thrombocytopenia or proteinuria was significantly different from that in normal controls, but not from that in patients with RA without these toxic reactions. Southern blot analysis of DR, DQ genes with cDNA probes showed that the extended haplotype bearing B8,DR3, which carries DQA2.1 and DQB2.1 genes, was present in a significantly higher proportion of patients with RA with gold induced thrombocytopenia or proteinuria (22/24, 92%) than in patients with RA without these side effects (32/45, 71%) or normal subjects (40/61, 66%). The data suggest that the genomic region on chromosome 6 involved in susceptibility to gold induced thrombocytopenia or proteinuria should be extended to the DQA2, DQB2 gene loci.

Full text

PDF
582

Images in this article

584Image
on p.584
584Image
on p.584

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Kassam Y., Powers P. J., Bianchi F. A., Cividino A., Kean W. F., Rooney P. J., Craig G. L., Buchanan W. W. Gold induced thrombocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum. 1987 May;16(4):287–293. doi: 10.1016/0049-0172(87)90006-0. [DOI] [PubMed] [Google Scholar]
  2. Bardin T., Dryll A., Debeyre N., Ryckewaert A., Legrand L., Marcelli A., Dausset J. HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis. Ann Rheum Dis. 1982 Dec;41(6):599–601. doi: 10.1136/ard.41.6.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bensen W. G., Moore N., Tugwell P., D'Souza M., Singal D. P. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):358–361. [PubMed] [Google Scholar]
  4. Canada A. T. Gold-induced thrombocytopenia. Am J Hosp Pharm. 1973 Apr;30(4):340–342. [PubMed] [Google Scholar]
  5. Chatila M., Luyrink L., McEleney J., Spies T., Strominger J. L., Glass D. N. Restriction fragment length polymorphisms and an HLA-DRw52-associated split. Hum Immunol. 1988 Feb;21(2):89–97. doi: 10.1016/0198-8859(88)90084-5. [DOI] [PubMed] [Google Scholar]
  6. Coblyn J. S., Weinblatt M., Holdsworth D., Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med. 1981 Aug;95(2):178–181. doi: 10.7326/0003-4819-95-2-178. [DOI] [PubMed] [Google Scholar]
  7. DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association. Ann Rheum Dis. 1959 Mar;18(1):49–53. [PMC free article] [PubMed] [Google Scholar]
  8. Dequeker J., Van Wanghe P., Verdickt W. A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):282–286. [PubMed] [Google Scholar]
  9. Festenstein H., Awad J., Hitman G. A., Cutbush S., Groves A. V., Cassell P., Ollier W., Sachs J. A. New HLA DNA polymorphisms associated with autoimmune diseases. Nature. 1986 Jul 3;322(6074):64–67. doi: 10.1038/322064a0. [DOI] [PubMed] [Google Scholar]
  10. Fielder A. H., Ollier W., Lord D. K., Burley M. W., Silman A., Awad J., Festenstein H., Batchelor J. R. HLA class III haplotypes in multicase rheumatoid arthritis families. Hum Immunol. 1989 Jun;25(2):75–85. doi: 10.1016/0198-8859(89)90072-4. [DOI] [PubMed] [Google Scholar]
  11. Gran J. T., Husby G., Thorsby E. HLA DR antigens and gold toxicity. Ann Rheum Dis. 1983 Feb;42(1):63–66. doi: 10.1136/ard.42.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hakala M., van Assendelft A. H., Ilonen J., Jalava S., Tiilikainen A. Association of different HLA antigens with various toxic effects of gold salts in rheumatoid arthritis. Ann Rheum Dis. 1986 Mar;45(3):177–182. doi: 10.1136/ard.45.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hurley C. K., Gregersen P., Steiner N., Bell J., Hartzman R., Nepom G., Silver J., Johnson A. H. Polymorphism of the HLA-D region in American blacks. A DR3 haplotype generated by recombination. J Immunol. 1988 Feb 1;140(3):885–892. [PubMed] [Google Scholar]
  14. Karr R. W., Rodey G. E., Lee T., Schwartz B. D. Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum. 1980 Nov;23(11):1241–1245. doi: 10.1002/art.1780231102. [DOI] [PubMed] [Google Scholar]
  15. Majoos F. L., Klemp P., Meyers O. L., Briggs B. Gold therapy in rheumatoid arthritis. S Afr Med J. 1981 Jun 27;59(27):971–974. [PubMed] [Google Scholar]
  16. Panayi G. S., Wooley P., Batchelor J. R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J. 1978 Nov 11;2(6148):1326–1328. doi: 10.1136/bmj.2.6148.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sigler J. W., Bluhm G. B., Duncan H., Sharp J. T., Ensign D. C., McCrum W. R. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med. 1974 Jan;80(1):21–26. doi: 10.7326/0003-4819-80-1-21. [DOI] [PubMed] [Google Scholar]
  18. Singal D. P., Butler L., Lamontagne L. Identification of two subtypes of HLA-DR2 by Southern blot analysis. Tissue Antigens. 1986 Jul;28(1):29–40. doi: 10.1111/j.1399-0039.1986.tb00457.x. [DOI] [PubMed] [Google Scholar]
  19. Singal D. P., D'Souza M., Reid B., Bensen W. G., Kassam Y. B., Adachi J. D. HLA-DQ beta-chain polymorphism in HLA-DR4 haplotypes associated with rheumatoid arthritis. Lancet. 1987 Nov 14;2(8568):1118–1120. doi: 10.1016/s0140-6736(87)91548-0. [DOI] [PubMed] [Google Scholar]
  20. Singal D. P., Green D., Reid B., D'Souza M. Polymorphism of three HLA-DR3-bearing major histocompatibility complex extended haplotypes. Immunogenetics. 1989;29(4):277–280. doi: 10.1007/BF00717914. [DOI] [PubMed] [Google Scholar]
  21. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  22. Stetler D., Grumet F. C., Erlich H. A. Polymorphic restriction endonuclease sites linked to the HLA-DR alpha gene: localization and use as genetic markers of insulin-dependent diabetes. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8100–8104. doi: 10.1073/pnas.82.23.8100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. SØRENSEN B. Case of fatal thrombopenia about 10 months after treatment with gold preparation. Acta Med Scand. 1951;141(1):27–35. doi: 10.1111/j.0954-6820.1951.tb14191.x. [DOI] [PubMed] [Google Scholar]
  24. Terasaki P. I., Bernoco D., Park M. S., Ozturk G., Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978 Feb;69(2):103–120. doi: 10.1093/ajcp/69.2.103. [DOI] [PubMed] [Google Scholar]
  25. Todd J. A., Bell J. I., McDevitt H. O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987 Oct 15;329(6140):599–604. doi: 10.1038/329599a0. [DOI] [PubMed] [Google Scholar]
  26. WOOLF B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955 Jun;19(4):251–253. doi: 10.1111/j.1469-1809.1955.tb01348.x. [DOI] [PubMed] [Google Scholar]
  27. Ward J. R., Williams H. J., Egger M. J., Reading J. C., Boyce E., Altz-Smith M., Samuelson C. O., Jr, Willkens R. F., Solsky M. A., Hayes S. P. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983 Nov;26(11):1303–1315. doi: 10.1002/art.1780261102. [DOI] [PubMed] [Google Scholar]
  28. Wescott M. Z., Awdeh Z. L., Yunis E. J., Alper C. A. Molecular analysis distinguishes two HLA-DR3-bearing major histocompatibility complex extended haplotypes. Immunogenetics. 1987;26(6):370–374. doi: 10.1007/BF00343707. [DOI] [PubMed] [Google Scholar]
  29. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  30. Zerbib A., Mølvig J., Thomsen M., Coppin H., Cambon-Thomsen A., Sommer E., Nerup J., De Preval C. Restriction fragment length polymorphism of HLA and non-HLA genes in DR3/4 heterozygous Danish insulin-dependent diabetic patients and healthy individuals: reassessment of the influence of alpha DX and insulin-linked polymorphic loci, and new splits of DQw3 haplotypes. Dis Markers. 1989 Jan-Mar;7(1):27–41. [PubMed] [Google Scholar]
  31. van Riel P. L., Reekers P., van de Putte L. B., Gribnau F. W. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens. 1983 Sep;22(3):194–199. doi: 10.1111/j.1399-0039.1983.tb01191.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES